Exact Sciences EXAS Operating Losses;.Another 70% to Fall!!
The EXAC chart has been a downtrend from $130 to $40 with a High VOLUME. The stock is making new bottoms while insiders and the executive team have constantly been selling at any price! The stock is down 70% from its high of $137! How many insiders bought any shares at $40? NONE! BIG ZERO! The technical chart is obvious. On the fundamentals:
Revenue of company lost -745Million on Revenue of $1.85 Billion! Cash incineration company highly leveraged!
Losing money fast is another indicator. The main product, Cologuard, is being advertised on TV for $680, cash $500. However, your doctor needs to order this! Most doctors, including my doctor, didn't want to use this versus colonoscopy because of liability and not a practical test with multiple false positives in case of blood and not detecting Polyps!
Cologuard is 92% accurate with 13% FALSE positive and 8% False Negative! The fit-tests that most doctors use to find blood in stool are $25-$49, then they recommend colonoscopy to see colon Polyps! This company bought tons of other companies at crazy valuations. The CEO is an attorney from Michigan state who comes to TV/CNBC on Cramer shows to pump and dump this stock to the public. (See youtube videos) The company has 3.5 billion in long-term and short-term liability with bad operating cash burns. The TV ads are the kiss of death to increase revenue at huge costs. Definition of stock that is 70% down then drops 2/3 to be 90% from its high.
Last Catherine Wood of ARK investment loves this stock owning 4.4% or 662million. I have seen Catie's garbage analysis on the stock with Tesla's $4600 target regardless of how many cars they sell! She is like Softbank putting her investment in shiny useless objects like Coinbase, upstart, and telehealth at crazy valuations.
Exact Science has NO SCIENCE or Exact.
EXAS will follow PACB $4, Pacific Bioscience to single-digit stock!
A crowded diagnostic market with many competitors, falling prices, and expensive doctors as customer acquisition will not work!
My 2 cents and do your homework, and I am not responsible for your trades.
Revenue of company lost -745Million on Revenue of $1.85 Billion! Cash incineration company highly leveraged!
Losing money fast is another indicator. The main product, Cologuard, is being advertised on TV for $680, cash $500. However, your doctor needs to order this! Most doctors, including my doctor, didn't want to use this versus colonoscopy because of liability and not a practical test with multiple false positives in case of blood and not detecting Polyps!
Cologuard is 92% accurate with 13% FALSE positive and 8% False Negative! The fit-tests that most doctors use to find blood in stool are $25-$49, then they recommend colonoscopy to see colon Polyps! This company bought tons of other companies at crazy valuations. The CEO is an attorney from Michigan state who comes to TV/CNBC on Cramer shows to pump and dump this stock to the public. (See youtube videos) The company has 3.5 billion in long-term and short-term liability with bad operating cash burns. The TV ads are the kiss of death to increase revenue at huge costs. Definition of stock that is 70% down then drops 2/3 to be 90% from its high.
Last Catherine Wood of ARK investment loves this stock owning 4.4% or 662million. I have seen Catie's garbage analysis on the stock with Tesla's $4600 target regardless of how many cars they sell! She is like Softbank putting her investment in shiny useless objects like Coinbase, upstart, and telehealth at crazy valuations.
Exact Science has NO SCIENCE or Exact.
EXAS will follow PACB $4, Pacific Bioscience to single-digit stock!
A crowded diagnostic market with many competitors, falling prices, and expensive doctors as customer acquisition will not work!
My 2 cents and do your homework, and I am not responsible for your trades.
İşlem aktif
When you listen to the last quarter conference call. The Exact Science (EXAS) lost 200M last quarter. 800M cash on the balance sheet and 4-quarter runway!!
They have a ton of useless M&A at high valuations with no product in near future, The blood diagnostic for Colon Cancer has less sensitivity (useless) than the existing Colorguard at $200 if approved! Oher cancer detections are too late in the crowded liquid diagnostic market.
Insiders have been selling when the stock is down from $130 to $38, not a single buyer!
LIQUIDITY will be a key issue. So, Major layoff of recent three billion acquisitions. (right off)
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.
Feragatname
Bilgiler ve yayınlar, TradingView tarafından sağlanan veya onaylanan finansal, yatırım, işlem veya diğer türden tavsiye veya tavsiyeler anlamına gelmez ve teşkil etmez. Kullanım Şartları'nda daha fazlasını okuyun.